Business
AVA3996 data poster presentation at AACR
AVA3996 data poster presentation at AACR.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n \n \n \n 27 March 2023\n \n \n \n \n \n \n \n \n Avacta Group plc\n \n \n \n \n \n \n \n \n (\"Avacta\" or the \"Company\" or, together with its subsidiary undertakings, the \"Group\")\n \n \n \n \n \n \n \n \n Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting\n \n \n \n \n \n \n \n \n Avacta Group plc (AIM: AVCT),\n a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics\n , announces it will present a poster entitled 'AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-\n \n a\n \n \n ) mediated cleavage'\n \n , at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place at Orange County Convention Center, Orlando, Florida on 16 April.\n \n \n \n \n \n The poster describes the data and pre-clinical rationale for the further development and disease positioning of the Company's second pre|CISION™ candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor. AVA3996 utilises Avacta's pre|CISION™ platform to improve the therapeutic index and therefore utility of proteasome inhibitors in tumours with high FAP levels, including both solid and haematological tumours. AVA3996 has the potential to deliver efficacious levels of the proteasome inhibitor warhead directly to the tumour microenvironment while reducing systemic exposure and hence associated toxicities, such as peripheral neuropathy.\n \n \n \n \n \n Attending the conference from Avacta will be\n Fiona McLaughlin - Chief Scientific Officer, Neil Bell - Chief Development Officer, David Jones - VP Biology and Francis Wilson - VP Chemistry.\n \n \n \n \n \n \n \n Poster presentation Title\n \n \n \n \n \n AVA3996, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein-alpha (FAP-a) mediated cleavage\n \n \n \n \n \n \n \n Session Category\n \n \n \n \n \n Experimental and Molecular Therapeutics\n \n \n \n \n \n \n \n Session Title\n \n \n \n \n \n Targeting the Tumor Microenvironment\n \n \n \n \n \n \n \n Session Date and Time\n \n \n \n \n \n Apr 16, 2023 1:30 PM - 5:30 PM ET\n \n \n \n \n \n \n \n Location\n \n \n \n \n \n Orange C...